GlassScriptPhysician profile
Mavi Rivera Pavon
NPI 1225683865
$4,975.59
in general payments reported to CMS, 2019-2025
21 companies · $4,009 in 2025
The $4,009 reported for 2025 was more than what 83% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $966 · 2025: $4,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,975.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,404.63 | 2024-2025 | Krystexxa, Otezla, Enbrel |
| Abbvie INC. | $739.39 | 2024-2025 | |
| Ucb, INC. | $665.52 | 2024-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $341.24 | 2024-2025 | |
| Pfizer INC. | $338.61 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $280.83 | 2024-2025 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $230.32 | 2025 | Orencia |
| Glaxosmithkline, LLC. | $225.02 | 2024-2025 | Benlysta |
| Fresenius Kabi USA, LLC | $124.58 | 2025 | Tyenne |
| Lilly USA, LLC | $109.82 | 2024-2025 | Taltz |
| Janssen Biotech, INC. | $109.55 | 2024-2025 | Tremfya |
| Organon LLC | $86.97 | 2025 | Hadlima, Renflexis |
| Sobi, INC | $56.54 | 2025 | |
| Genentech USA, INC. | $50.80 | 2025 | Actemra, Gazyva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.00 | 2024-2025 | Ofev |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $37.93 | 2024 | Zilretta |
| Astrazeneca Pharmaceuticals LP | $35.92 | 2025 | Saphnelo |
| Radius Health, INC. | $28.10 | 2024 | Tymlos |
| Aurinia Pharma U.S., INC. | $25.05 | 2024 | Lupkynis |
| Gc Biopharma USA, INC. | $20.78 | 2025 | Alyglo |
| Invivyd INC | $13.99 | 2025 | Pemgarda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mavi Rivera Pavon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.